Comment on: “Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus” Richard A. Furie et al. NEJM March 2026
Commented by: Karoline Lerang, Department of Rheumatology, Oslo University Hospital- NORWAY
Nearly 15 years after the EXPLORER and LUNAR trials failed in systemic lupus erythematosus (SLE), obinutuzumab—a type II anti-CD20 antibody developed by Roche—has succeeded, meeting both primary and secondary endpoints in randomized controlled trials.
The phase 3 ALLEGORY trial (New England Journal of Medicine, March 2026) randomized 303 patients with active SLE (excluding lupus nephritis and CNS disease) to obinutuzumab or placebo on top of standard therapy. The primary endpoint was SRI-4 response at week 52.
Obinutuzumab showed clear benefit. SRI-4 response was achieved in 76.7% versus 53.5% with placebo. Secondary outcomes also favored treatment: more patients reduced glucocorticoids to ≤7.5 mg/day (80.0% vs. 54.1%), fewer had BILAG flares (33.8% vs. 48.7%), and remission and low disease activity rates were higher (DORIS: 35.1% vs. 13.8%; LLDAS: 57.6% vs. 25.0%). These results address key unmet needs, particularly steroid sparing and flare prevention.
Earlier trials with rituximab showed biological effects but limited clinical benefit, likely due to incomplete B-cell depletion, especially in tissues, along with trial design and glucocorticoid confounding.
Obinutuzumab induces deeper and more sustained B-cell depletion through enhanced cellular cytotoxicity and direct cell death, and appears more effective in tissue.
Emerging evidence suggests that active SLE requires deeper levels of B-cell depletion, a concept supported by the profound remissions observed with CAR-T therapies that induce near-complete B-cell depletion. The ALLEGORY trial supports this concept and positions obinutuzumab as an important advance for patients with active SLE despite standard therapy.
